To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. Our first job is to listen to and observe what our customers need, and meet those needs with quality products and services. While we are not currently experiencing delays due to this pandemic, we expect that we could see them as the situation evolves. If you experience any issues, please contact ATCC Customer Service at For Technical questions please contact Thank you for your understanding, patience and flexibility as ATCC does everything it can to help reduce the impact of the coronavirus pandemic to our valued customers.

SNU-449 (ATCC® CRL-2234)

Organism: Homo sapiens, human  /  Tissue: liver  /  Disease: grade II-III/IV, hepatocellular carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue liver
Product Format frozen
Morphology epithelial; diffusely spreading cells
Culture Properties adherent
Biosafety Level 2  [Cells contain Hepatitis B virus]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease grade II-III/IV, hepatocellular carcinoma
Age 52 years
Gender male
Ethnicity Asian
Storage Conditions liquid nitrogen vapor phase
Karyotype aneuploid; modal number = 57
Images ATCC CRL-2234 Cell Micrograph

SNU-449 was derived in 1990 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient prior to cytotoxic therapy.

Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat inactivated fetal bovine serum. After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum.
Clinical Data
52 years


Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization. HBV genomic RNA was not expressed.

Grossly, the original tumor was single nodular with perinodular extensions. Histologically, it was predominantly compact and minor trabecular type.

The cultured cells contain a single or double nucleus.

ATCC confirmed this cell line is positive for the presence of Hepatitis B viral DNA sequences.

Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:5 to 1:10
Medium Renewal: 2 to 3 times a week.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.

Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Population Doubling Time 36 hrs
Name of Depositor J Park
Deposited As Homo sapiens
Year of Origin 1990

Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

This line is available under the following restrictions: 1.) The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.) Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. Telephone (02) 760-3380, Fax (02) 742-4727. 3.) In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication (Int. J. Cancer 62:276-282, 1995).


Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080